Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Tipo de documento
Ano de publicação
Intervalo de ano de publicação
1.
Neuroscience ; 416: 239-254, 2019 09 15.
Artigo em Inglês | MEDLINE | ID: mdl-31400487

RESUMO

Given their anti-inflammatory properties, cannabinoids have been shown to be neuroprotective agents and to reduce excitotoxicity, through the activation of the Cannabinoid receptor type 1 (CB1r). These properties have led to CB1r being proposed as pharmacological targets for the treatment of various neurodegenerative diseases. Amyloid-ß 25-35 (Aß25-35) induces the expression of inducible nitric oxide synthase (iNOS) and increases nitric oxide (NO●) levels. It has been observed that increased NO● concentrations trigger biochemical pathways that contribute to neuronal death and cognitive damage. This study aimed to evaluate the neuroprotective effect of an acute activation of CB1r on spatial memory and its impact on iNOS protein expression, NO● levels, gliosis and the neurodegenerative process induced by the injection of Aß(25-35) into the CA1 subfield of the hippocampus. ACEA [1 µM/1 µL] and Aß(25-35) [100 µM/1 µL] and their respective vehicle groups were injected into the CA1 subfield of the hippocampus. The animals were tested for spatial learning and memory in the eight-arm radial maze, with the results revealing that the administration of ACEA plus Aß(25-35) improves learning and memory processes, in contrast with the Aß(25-35) group. Moreover, ACEA plus Aß(25-35) prevented both the increase in iNOS protein and NO● levels and the reactive gliosis induced by Aß(25-35). Importantly, neurodegeneration was significantly reduced by the administration of ACEA plus Aß(25-35) in the CA1 subfield of the hippocampus. The data obtained in the present research suggest that the acute early activation of CB1r is crucial for neuroprotection.


Assuntos
Ácidos Araquidônicos/farmacologia , Transtornos da Memória/induzido quimicamente , Degeneração Neural/tratamento farmacológico , Receptor CB1 de Canabinoide/agonistas , Memória Espacial/efeitos dos fármacos , Peptídeos beta-Amiloides/farmacologia , Animais , Proteínas de Ligação ao Cálcio/metabolismo , Proteína Glial Fibrilar Ácida/metabolismo , Gliose/tratamento farmacológico , Gliose/metabolismo , Hipocampo/metabolismo , Masculino , Aprendizagem em Labirinto/efeitos dos fármacos , Transtornos da Memória/prevenção & controle , Proteínas dos Microfilamentos/metabolismo , Fármacos Neuroprotetores/farmacologia , Óxido Nítrico/metabolismo , Óxido Nítrico Sintase Tipo II/metabolismo , Fragmentos de Peptídeos/farmacologia , Ratos , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA